Gary Fanger, PhD, has 20+ years of experience in the biotechnology industry developing novel therapeutics, establishing drug development alliances, and leading M&A activities. He serves as a director on the boards of Virtici and formerly OncoImmune, where Gary helped support the $425M acquisition by Merck in 2020.
In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Gary helped build this start-up out of Johns Hopkins University and led the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Gary was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Gary was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances.
Gary has co-authored over 50 articles and reviews in peer-reviewed journals in the areas of monoclonal antibody development, cell biology and cancer research. He has also been awarded 35 patents. Gary received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.
In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Gary helped build this start-up out of Johns Hopkins University and led the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Gary was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Gary was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances.
Gary has co-authored over 50 articles and reviews in peer-reviewed journals in the areas of monoclonal antibody development, cell biology and cancer research. He has also been awarded 35 patents. Gary received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.
Speaking In
4:30 PM - 4:45 PM
Monday, June 5
